Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM3 | Q86V86 | 2/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 9/20 | 0.46 |
| ▸ | BRAF | P15056 | 4/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931446 | 0.91 | MCHR1 (0.43) | PIM3MCHR1PFKFB3 | |
| Trifluoroacetic Acid SCHEMBL2970750 | 0.91 | PIM3 (0.46) | PIM3MCHR1BRAFRAF1IGF1R | |
| SCHEMBL13515293 | 0.90 | PIM3 (0.49) | PIM3MCHR1BRAFRAF1IGF1R | |
| SCHEMBL2931441 | 0.84 | BRAF (0.46) | PIM3MCHR1BRAFRAF1IGF1R | |
| SCHEMBL2933168 | 0.84 | PFKFB3 (0.40) | MCHR1PFKFB3 | |
| SCHEMBL2933931 | 0.82 | PIM3 (0.53) | PIM3BRAFRAF1SYK | |
| Trifluoroacetic Acid SCHEMBL2931444 | 0.81 | MCHR1 (0.42) | PIM3MCHR1SYKPFKFB3 | |
| Trifluoroacetic Acid SCHEMBL2927211 | 0.80 | BRAF (0.39) | PIM3MCHR1BRAFPTK2 | |
| SCHEMBL13515309 | 0.80 | MCHR1 (0.44) | PIM3MCHR1BRAFIGF1RSYK | |
| SCHEMBL13515287 | 0.79 | MCHR1 (0.45) | PIM3MCHR1BRAFPFKFB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | PIM3 2131/4885MCHR1 1686/4885BRAF 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.